✦ LIBER ✦

P-594 Extended survival in stage IV patients treated with low dose maintained chemotherapy

✍ Scribed by Yamaguchi, N.; Rangel-Pestana, D.; Vargas, F.; Araujo, M.; Donatangelo, S.; Marini, A.; Naves, A.; Souza, A.; Cordeiro, I.; Bevilacqua, R.

Book ID: 118573498
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 272 KB
Volume: 49
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(05)81087-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High-dose chemotherapy with autologous s

High-dose chemotherapy with autologous stem cell support in patients with responding stage IV breast cancer

✍ Ljungman, P; Björkstrand, B; Fornander, T; Höglund, M; Juliusson, G; Lindman, H; 📂 Article 📅 1998 🏛 Nature Publishing Group 🌐 English ⚖ 45 KB

Long-term follow-up of advanced-stage lo

Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft

✍ Tarella, C; Caracciolo, D; Corradini, P; Zallio, F; Ladetto, M; Cuttica, A; Ross 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 122 KB

Dose intensity correlate with survival i

Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer

✍ Luciani, A.; Bertuzzi, C.; Ascione, G.; Di Gennaro, E.; Bozzoni, S.; Zonato, S.; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 146 KB

ERCC1, hRad51, and BRCA1 protein express

ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy

✍ Wachters, F.M.; Wong, L.S.M.; Timens, W.; Kampinga, H.H.; Groen, H.J.M. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 456 KB

High-dose alkylating agent chemotherapy

High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer

✍ Elizabeth J. Shpall; Daniel Clarke-Pearson; John T. Soper; Andrew Berchuck; Roy 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 639 KB

Second-line, low-dose, weekly paclitaxel

Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel

✍ Mark A. Socinski; Michael J. Schell; Kamal Bakri; Amy Peterman; Ji-Hyun Lee; Pau 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 2 views

## Abstract ## BACKGROUND Second‐line chemotherapy with docetaxel improves survival and quality of life (QoL) in patients with nonsmall cell lung carcinoma (NSCLC) who fail first‐line platinum‐based regimens. The authors sought to determine the activity of second‐line, low‐dose, weekly paclitaxel